Fabrinet vs Stryker Corporation — how do they compare? Fabrinet trades at $489.21 (market cap $17.46B), while Stryker Corporation trades at $277.29 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 6.1× Fabrinet's market cap, and Stryker Corporation pays a 1.27% dividend while Fabrinet pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and Stryker Corporation for 21 Days on average.
| FN | SYK | |
|---|---|---|
Market Cap | $17.46B | $106.24B |
Volume | 1,199,886 | 2,982,001 |
Sector | Technology | Health |
52-Week High | $746.47 | $388.35 |
52-Week Low | $361.94 | $269.75 |
Typical Hold Time | 30 Days | 21 Days |
Enterprise Value | $16.59B | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $493.25, down 0.95% amid mixed technical signals with bullish moving averages but overbought RSI readings. The company demonstrates strong fundamental performance with 45% Q4 revenue growth and consistent earnings beats, driven by surging AI data center demand. Analyst consensus remains strongly bullish with a $769.50 price target representing 56% upside potential, though the stock faces near-term pressure from high capital expenditures.
Fabrinet's AI infrastructure positioning and capacity expansion support long-term growth prospects, but investors should monitor customer concentration risks and margin pressures. The stock's premium valuation (P/E 37.34) requires continued execution on growth targets to justify current levels amid competitive optical component market dynamics.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →